U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07576608) titled 'A Phase II Study of 9MW3811 in Patients With Pathological Scar' on April 12.
Brief Summary: This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.
Study Start Date: Dec. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Scar
Intervention:
DRUG: 9MW3811 Injection
9MW3811 is a recombinant humanized monoclonal antibody targeting interleukin-11 (IL-11). It is administered intravenously.
DRUG: Placebo
Matching placebo solution with no active ingredient, administered intravenously.
Recruit...